New Projects information at Drug Development Technology New and updated information from Projects listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New Projects information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Aliqopa (copanlisib) for the Treatment of Relapsed Follicular Lymphoma http://www.drugdevelopment-technology.com/projects/aliqopa-copanlisib-for-the-treatment-of-relapsed-follicular-lymphoma/ http://www.drugdevelopment-technology.com/projects/aliqopa-copanlisib-for-the-treatment-of-relapsed-follicular-lymphoma/ Aliqopa (copanlisib) is a novel intravenous phosphatidylinositol-3-kinase (PI3K) inhibitor indicated for the treatment of adult patients with relapsed follicular lymphoma (FL). Thu, 21 Sep 2017 23:00:00 GMT Lartruvo (olaratumab) for the Treatment of Soft Tissue Sarcoma http://www.drugdevelopment-technology.com/projects/lartruvo-olaratumab-for-the-treatment-of-soft-tissue-sarcoma/ http://www.drugdevelopment-technology.com/projects/lartruvo-olaratumab-for-the-treatment-of-soft-tissue-sarcoma/ Developed by Eli Lilly and Company, Lartruvo (olaratumab) in combination with doxorubicin is indicated for the treatment of soft tissue sarcoma (STS) in adult patients. The drug is available as a 10mg/ml injection. Wed, 13 Sep 2017 23:00:00 GMT Kymriah (tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukaemia http://www.drugdevelopment-technology.com/projects/kymriah-tisagenlecleucel-for-the-treatment-of-acute-lymphoblastic-leukaemia/ http://www.drugdevelopment-technology.com/projects/kymriah-tisagenlecleucel-for-the-treatment-of-acute-lymphoblastic-leukaemia/ Kymriah (tisagenlecleucel) is the first chimeric antigen receptor T cell (CAR-T) therapy approved in the US for the treatment of paediatric and young adult patients with B-cell precursor acute lymphoblastic leukaemia (ALL). Tue, 12 Sep 2017 23:00:00 GMT KamRAB/KedRAB (rabies immunoglobulin human) for the Treatment of Rabies http://www.drugdevelopment-technology.com/projects/kamrabkedrab-rabies-immunoglobulin-human-for-the-treatment-of-rabies/ http://www.drugdevelopment-technology.com/projects/kamrabkedrab-rabies-immunoglobulin-human-for-the-treatment-of-rabies/ KamRAB/KedRAB™ is a human rabies immunoglobulin (HRIG) indicated for the treatment of passive, transient post-exposure prophylaxis (PEP) of rabies infection. The drug was jointly developed by Kamada and Kedrion Biopharma. Thu, 07 Sep 2017 23:00:00 GMT Duzallo (allopurinol and lesinurad) for the Treatment of Hyperuricemia Associated with Gout http://www.drugdevelopment-technology.com/projects/duzallo-allopurinol-and-lesinurad-for-the-treatment-of-hyperuricemia-associated-with-gout/ http://www.drugdevelopment-technology.com/projects/duzallo-allopurinol-and-lesinurad-for-the-treatment-of-hyperuricemia-associated-with-gout/ Duzallo (allopurinol and lesinurad) is indicated for the treatment of hyperuricemia associated with uncontrolled gout. It contains urate transporter-1 (URAT-1) inhibitor blended with xanthine oxidase inhibitor (XOI). Tue, 29 Aug 2017 23:00:00 GMT Nerlynx (neratinib) for the Treatment of Breast Cancer http://www.drugdevelopment-technology.com/projects/nerlynx-neratinib-for-the-treatment-of-breast-cancer/ http://www.drugdevelopment-technology.com/projects/nerlynx-neratinib-for-the-treatment-of-breast-cancer/ Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult patients with early-stage HER2-overexpressed or amplified breast cancer. Wed, 23 Aug 2017 23:00:00 GMT Idhifa (enasidenib) for the Treatment of Acute Myeloid Leukaemia (AML) http://www.drugdevelopment-technology.com/projects/idhifa-enasidenib-for-the-treatment-of-acute-myeloid-leukaemia-aml/ http://www.drugdevelopment-technology.com/projects/idhifa-enasidenib-for-the-treatment-of-acute-myeloid-leukaemia-aml/ Idhifa (enasidenib) is an isocitrate dehydrogenase 2 (IDH2) enzyme inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML). Thu, 17 Aug 2017 23:00:00 GMT MAVYRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C http://www.drugdevelopment-technology.com/projects/mavyret-glecaprevirpibrentasvir-for-the-treatment-of-chronic-hepatitis-c/ http://www.drugdevelopment-technology.com/projects/mavyret-glecaprevirpibrentasvir-for-the-treatment-of-chronic-hepatitis-c/ MAVYRET™ (glecaprevir/pibrentasvir) was developed by US-based biopharmaceutical company AbbVie as a pan-genotypic treatment for adults suffering from chronic hepatitis C virus (HCV) infection across six major genotypes (GT1 to GT6). Tue, 08 Aug 2017 23:00:00 GMT Vosevi™ for the Retreatment of Chronic Hepatitis C Virus Infection http://www.drugdevelopment-technology.com/projects/vosevi-for-the-retreatment-of-chronic-hepatitis-c-virus-infection/ http://www.drugdevelopment-technology.com/projects/vosevi-for-the-retreatment-of-chronic-hepatitis-c-virus-infection/ Vosevi™ (Sofosbuvir/Velpatasvir/Voxilaprevir) is a direct-acting antiviral (DAA) indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults with genotypes one to six. Thu, 27 Jul 2017 23:00:00 GMT Tremfya (guselkumab) for the Treatment of Plaque Psoriasis http://www.drugdevelopment-technology.com/projects/tremfya-guselkumab-for-the-treatment-of-plaque-psoriasis/ http://www.drugdevelopment-technology.com/projects/tremfya-guselkumab-for-the-treatment-of-plaque-psoriasis/ Tremfya™ (guselkumab) is a biologic approved for the treatment of adults living with moderate to severe plaque psoriasis. Tue, 25 Jul 2017 23:00:00 GMT Endari for the Treatment of Sickle Cell Disease http://www.drugdevelopment-technology.com/projects/endari-for-the-treatment-of-sickle-cell-disease/ http://www.drugdevelopment-technology.com/projects/endari-for-the-treatment-of-sickle-cell-disease/ Endari™ is an orally-administered powder form of amino acid L-glutamine indicated for the treatment of sickle cell disease. Sun, 23 Jul 2017 23:00:00 GMT Haegarda for the Preventive Treatment of Hereditary Angioedema http://www.drugdevelopment-technology.com/projects/haegarda-for-the-preventive-treatment-of-hereditary-angioedema/ http://www.drugdevelopment-technology.com/projects/haegarda-for-the-preventive-treatment-of-hereditary-angioedema/ Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients. Wed, 12 Jul 2017 23:00:00 GMT Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections http://www.drugdevelopment-technology.com/projects/baxdela-delafloxacin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections/ http://www.drugdevelopment-technology.com/projects/baxdela-delafloxacin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections/ Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Lig… Thu, 06 Jul 2017 23:00:00 GMT Zykadia (Ceritinib) Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) http://www.drugdevelopment-technology.com/projects/zykadia-ceritinib-treatment-metastatic-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/zykadia-ceritinib-treatment-metastatic-non-small-cell-lung-cancer-nsclc/ Zykadia (Ceritinib / LDK378) is an inhibitor of anaplastic lymphoma kinase (ALK) indicated for treatment of non-small cell lung cancer (NSCLC). Thu, 06 Jul 2017 23:00:00 GMT Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder http://www.drugdevelopment-technology.com/projects/mydayis-for-the-treatment-of-attention-deficit-hyperactivity-disorder/ http://www.drugdevelopment-technology.com/projects/mydayis-for-the-treatment-of-attention-deficit-hyperactivity-disorder/ Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and above. Thu, 29 Jun 2017 23:00:00 GMT Truxima (rituximab) for the Treatment of Cancer http://www.drugdevelopment-technology.com/projects/truxima-rituximab-for-the-treatment-of-cancer/ http://www.drugdevelopment-technology.com/projects/truxima-rituximab-for-the-treatment-of-cancer/ ruxima™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well… Thu, 08 Jun 2017 23:00:00 GMT Kevzara (sarilumab) for the Treatment of Rheumatoid Arthritis http://www.drugdevelopment-technology.com/projects/kevzara-sarilumab-for-the-treatment-of-rheumatoid-arthritis/ http://www.drugdevelopment-technology.com/projects/kevzara-sarilumab-for-the-treatment-of-rheumatoid-arthritis/ Kevzara® (sarilumab) is a human monoclonal antibody indicated for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA). Sun, 04 Jun 2017 23:00:00 GMT Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC) http://www.drugdevelopment-technology.com/projects/tecentriq-atezolizumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ http://www.drugdevelopment-technology.com/projects/tecentriq-atezolizumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ Tecentriq® (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1. Wed, 31 May 2017 23:00:00 GMT Dinutuximab beta for the Treatment of Neuroblastoma http://www.drugdevelopment-technology.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/ http://www.drugdevelopment-technology.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/ Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above. Thu, 18 May 2017 23:00:00 GMT Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC) http://www.drugdevelopment-technology.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/ Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC). Tue, 16 May 2017 23:00:00 GMT